MA-ROSLINCT
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of experience in higher education, medical research, and organisational leadership. Currently serving as the Principal of the University of Edinburgh since 2018, Sir Peter also holds Honorary Professorships in Medicine at the Universities of Edinburgh, Hong Kong, and Bristol. His illustrious career includes notable roles such as President of the University of Hong Kong (2014-18) and Dean of the Faculty of Medicine & Dentistry at the University of Bristol (2008-14). Sir Peter was knighted in the 2023 New Year Honours for his services to higher education, reflecting his significant contributions to the field. Additionally, Sir Peter has held numerous non-executive and trustee roles, including positions with the Renal Association, Council for the Advancement and Support of Education (CASE), Scottish Funding Council, and Newbattle Abbey College Trust. His career highlights also include tenure as an honorary consultant nephrologist with a clinical interest in autoimmune diseases and renal transplantation. He has led a significant research group in Bristol and contributed extensively to medical education and clinical research, particularly in Africa. His publication record includes 327 works, covering clinical trials, laboratory research, and societal matters, and he has been a driving force in academic careers both in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience, specializing in biopharmaceuticals and cell & gene therapy. He started at McKinsey & Co. and held executive roles at Genzyme Therapeutics Europe. He was CEO of MediService AG, PAION AG's Deputy-CEO and COO, and led PharmaCell BV to a successful sale to Lonza. Vos also served as CEO of VarmX and VectorY, setting strategy and raising significant funds for these companies. Currently, he sits on several biotech boards and is a Venture Partner at BioGeneration Ventures. He holds an MS in Pharmacy and Pharmacology and an MBA from Stanford University. Alexander Vos's proven leadership in advancing innovative therapies and achieving successful exits for investors will be invaluable to RoslinCT. His skills in biotech strategy development, operations, and M&A will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson and Alexander Vos to our Board," said Geoffrey Hamilton Fairley, Executive Chairman of the RoslinCT Group. "Sir Peter's extensive experience in academic leadership and his proven track record in advancing medical research and education, combined with Alexander's strategic insight and wealth of experience in biotech and cell and gene therapy, align perfectly with RoslinCT's mission. Their combined expertise will be instrumental as we continue to develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the company and the field of cell and gene therapy," said Sir Peter Mathieson. "I look forward to contributing to RoslinCT's innovative efforts to bring life-saving therapies to patients worldwide."
Alexander Vos added, "I am excited to be part of RoslinCT's journey and to support its mission to advance cell and gene therapies. The company is at the forefront of groundbreaking science, and I am eager to contribute to its continued success."
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Relaunches Company Magazine CATch UP to Showcase the Best of the Brand12.11.2025 10:00:00 CET | Press release
Sports company PUMA has relaunched its online company magazine CATch UP to provide journalists, investors, retailers, athletes and sports enthusiasts with a window into the world of PUMA and insights into the company’s new strategic priorities, as the brand starts its transformation journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112815459/en/ Sports company PUMA has relaunched its online company magazine CATch UP to provide journalists, investors, retailers, athletes and sports enthusiasts with a window into the world of PUMA and insights into the company’s new strategic priorities, as the brand starts its transformation journey. The online magazine, which is available on puma-catchup.com, has received a thorough visual makeover and will focus on the stories that highlight the company’s innovations, sports, history, corporate culture and the strategic priorities that are being implemented to establish PUMA as a T
CWAN Report: Insurance Industry’s $2.7 Trillion Shift to Alternative Investments Creates Technology Gap12.11.2025 10:00:00 CET | Press release
CWAN Analysis of 400 Insurers Shows Some Insurers Now Allocate 40-50% in ‘Alternatives’ Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today released industry research revealing that alternative investments have fundamentally transformed from a fringe strategy to a portfolio cornerstone, now comprising nearly one-third of the US insurance industry’s assets – representing approximately $2.7 trillion – as insurers abandon traditional portfolio strategies. Similar structural shifts are also emerging across the UK and continental Europe as insurers pursue diversification, yield and liability-matching under Solvency II and evolving capital rules. The report, “Are ‘Alternatives’ Still Alternative?”, combines industry-wide NAIC data with analysis of approximately 400 CWAN insurers representing $4.4 trillion in combined assets, including UK and European insurers on the CWAN platform, providing granular insight into alternative investmen
INNIO to Power UK Grid Stability with Landmark Project Near London12.11.2025 09:00:00 CET | Press release
One of the world’s largest high-speed gas engine power plants will provide 450 MW of scalable power Power plant to support grid stability in Southeast England, powering up to 1 million homes near London INNIO Group and Clarke Energy are helping to deliver one of the world’s largest high-speed gas engine peaking power plants in Thurrock, England. The two companies already signed a contract to this effect in 2024. The 450-MW flexible generation facility is being constructed by Statera Energy, a leading developer, owner, and operator of flexible energy assets. With full operations targeted for late 2026, it is expected to provide enough power for up to 1 million homes in Southeast England—helping to support the UK’s energy resilience strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112767813/en/ Thurrock Flexible Generation Project (c) Statera Energy As the UK transitions to renewables, grid stability is more critica
Visa Direct Stablecoin Payouts Pilot Speeds Up Access to Funds for Creators & Gig Workers12.11.2025 09:00:00 CET | Press release
New Visa Direct pilot sends USD-backed stablecoin payouts directly to stablecoin wallets, giving creators and gig workers faster access to their funds. At Web Summit today, Visa Inc. (V) announced a breakthrough pilot allowing businesses and platforms to send payouts directly to recipients’ stablecoin wallets. For businesses using Visa Direct, payouts can be funded in fiat currency, while recipients can choose to receive their funds in USD-backed stablecoins like USDC, transforming the speed and accessibility of global payouts. This innovation expands the reach of Visa Direct by providing creators, freelancers, and marketplaces with a stable store of value and faster access to funds - even in markets facing currency volatility or limited banking infrastructure. “Launching stablecoin payouts is about enabling truly universal access to money in minutes - not days - for anyone, anywhere in the world,” said Chris Newkirk, President, Commercial & Money Movement Solutions, Visa. “Whether it’
Ant International Launches World’s First Iris Authentication Feature in Smart-glasses Payment Solution12.11.2025 08:48:00 CET | Press release
Alipay+ GlassPay, Ant International’s smart glasses-embedded payment solution, will add iris authentication to its security verification capabilities, alongside voiceprint authentication The enhanced solution improves consumer checkout experience and merchant payment success rate, and opens a new channel for personalised customer interaction Ant International continues to push the frontiers of payment technology, adding to recent developments including AI-powered agentic payments and NFC-based integration of QR and card payments In a global first, Ant International, a leading global digital payment, digitisation, and financial technology provider, has added iris authentication features to Alipay+ GlassPay, its AR glasses-embedded payment solution, through partnerships with leading smart glasses producers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111892620/en/ The enhanced solution improves consumer checkout experien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom